This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Palatin Technologies, Inc. (PTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palatin (PTN) Begins Phase III Study For Dry Eye Disease
by Zacks Equity Research
Palatin (PTN) commences the pivotal phase III study evaluating PL9643 for the treatment of dry eye disease. Top-line data from the same is expected in the second half of 2022.
Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -100.00% and -182.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Palatin (PTN) Jumps: Stock Rises 8.7%
by Zacks Equity Research
Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Palatin (PTN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.
Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (PTN) Outperforming Other Medical Stocks This Year?
Palatin Technologies (PTN) Surges: Stock Moves 8% Higher
by Zacks Equity Research
Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline updates, when Palatin (PTN) releases fourth-quarter fiscal 2019 results.
Palatin (PTN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Palatin (PTN) closed at $0.91, marking a -1.7% move from the previous day.
Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PTN) Outperforming Other Medical Stocks This Year?
Palatin (PTN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Palatin (PTN) closed at $0.93 in the latest trading session, marking a -1.74% move from the prior day.
Palatin (PTN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Palatin (PTN) closed the most recent trading day at $1, moving +0.37% from the previous trading session.
Is Palatin Technologies (PTN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (PTN) Outperforming Other Medical Stocks This Year?
Palatin Technologies (PTN) in Focus: Stock Moves 5.7% Higher
by Zacks Equity Research
Palatin Technologies (PTN) shares rose nearly 6% in the last trading session, amid huge volumes.
Earnings Preview: Palatin (PTN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Palatin (PTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Palatin Technologies (PTN) in Focus: Stock Moves 13.2% Higher
by Zacks Equity Research
Palatin Technologies (PTN) was a big mover last session, as the company saw its shares rise more than 13% on the day.
AMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of 99 cents per share in the first quarter of 2017 compared with earnings of 68 cents in the year-ago quarter
Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%
by Zacks Equity Research
Dicerna Pharmaceuticals, Inc. (DRNA) shares rose over 14% in the last trading session.
AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) reported adjusted earnings of $1.36 per share in the fourth quarter of 2016, up from $1.04 in the year ago quarter.
Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
by Indradip Ghosh
Palatin Technologies, Inc. (PTN) has been struggling lately, but the selling pressure may be coming to an end soon.
AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
by Zacks Equity Research
AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.